Coronary Calcification and Cardiovascular Risk in Lung Cancer Patients

Coronary artery disease (CAD) and lung cancer share several risk factors, making it crucial to understand their interrelationship, especially in patients with non-small cell lung cancer (NSCLC). This study investigates the association between coronary artery calcification (CAC) and vascular inflammation with cardiovascular events in 119 NSCLC patients who underwent both chest computed tomography (CT) and 18F-FDG-PET/CT. The findings indicate that a high CAC score (≥100) correlates with a significantly lower cardiovascular event-free survival in patients with advanced lung cancer (stage III or IV) compared to those with a low CAC score (<100). In contrast, vascular inflammation, assessed through the maximum target-to-background ratio (TBR_max), did not show a significant association with cardiovascular outcomes. The study's results suggest that monitoring CAC in NSCLC patients, particularly those with advanced stages, could be vital for predicting cardiovascular risks. Specifically, patients with a high CAC score exhibited a trend towards lower cardiovascular event-free survival (Log rank, P = 0.105), which became statistically significant (P = 0.029) in advanced stages. Interestingly, for early-stage lung cancer patients (stage 0-II), cardiovascular event-free survival was similar regardless of CAC scores, indicating that the risk may escalate with disease progression. For individuals managing their metabolic health, these findings underscore the importance of regular cardiovascular assessments, especially for those diagnosed with lung cancer. Patients and healthcare providers should consider integrating CAC screening into routine evaluations to better understand cardiovascular risks and tailor interventions accordingly. This proactive approach may help in early identification and management of potential cardiovascular events, improving overall patient outcomes. This research connects to several biomarkers relevant to metabolic health, including coronary artery calcification, which can be assessed through imaging techniques. While vascular inflammation markers like TBR_max did not correlate with cardiovascular outcomes in this study, monitoring inflammation through biomarkers such as hsCRP could still be beneficial in a broader context. Understanding these relationships can empower patients to take charge of their metabolic health through informed lifestyle choices and medical interventions. In conclusion, the key takeaway from this study is the significant association between coronary artery calcification and cardiovascular risks in advanced lung cancer patients. Regular monitoring of CAC could serve as a critical tool in managing not only lung cancer but also associated cardiovascular health, highlighting the need for integrated care approaches.